|
Roche announces donation of essential medicines to Ukraine
|
02 March 2022 |
|
WHO grants prequalification of Actemra/RoActemra for patients with severe or critical COVID-19
|
14 February 2022 |
|
Roche completed the repurchase of Roche shares from Novartis
|
06 December 2021 |
|
CHMP recommends EU approval of Ronapreve to treat non-hospitalised COVID-19 patients and for prophylaxis of the disease
|
11 November 2021 |
|
Roche launches comprehensive genomic profiling kit to expand access to personalised cancer research
|
26 October 2021 |
|
Roche's anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer's disease
|
13 October 2021 |
|
Phase II/III trial shows Ronapreve™ (casirivimab and imdevimab) significantly reduces viral load in patients hospitalised with COVID-19
|
30 September 2021 |
|
Roche opens access to pathology imaging tools to improve patient care
|
17 September 2021 |
|
Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19
|
23 July 2021 |
|
Roche's Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children
|
25 June 2021 |
|
European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia
|
25 May 2021 |
|
Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%
|
12 April 2021 |
|
New phase III data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19
|
25 March 2021 |
|
Roche announces the upcoming launch of the SARS-CoV-2 Rapid Antigen Test Nasal allowing for patient self-collection
|
04 February 2021 |
|
Roche confirms US government agreement to purchase additional doses of Regeneron's casirivimab and imdevimab
|
19 January 2021 |
|
Roche announces collaboration with Atea Pharmaceuticals to develop a potential oral treatment for COVID-19 patients
|
28 October 2020 |
|
Roche and Regeneron collaborate to significantly increase global supply of REGN-COV2 investigational antibody combination for COVID-19
|
20 August 2020 |
|
Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia
|
28 May 2020 |
|
Roche's COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark
|
06 May 2020 |
|
Roche response to COVID-19 pandemic
|
26 March 2020 |